Jolanda Brummelman

8PUBLICATIONS
63CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 20, 2023
Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo.

Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman

|Dec 17, 2021
Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer.

Michela Masetti, Roberta Carriero, Federica Portale

|Oct 28, 2021
Author Correction: Single-cell profiling defines the prognostic benefit of CD39high tissue resident memory CD8+ T cells in luminal-like breast cancer.

Agnese Losurdo, Caterina Scirgolea, Giorgia Alvisi

|Oct 07, 2021
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice.

Jolien M R Van der Meer, Paul K J D de Jonge, Anniek B van der Waart

|Sep 23, 2021
Single-cell profiling defines the prognostic benefit of CD39high tissue resident memory CD8+ T cells in luminal-like breast cancer.

Agnese Losurdo, Caterina Scirgolea, Giorgia Alvisi

|May 21, 2021
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression.

Raoul J P Bonnal, Grazisa Rossetti, Enrico Lugli

Pageof 2

Frequent Collaborators

6 joint publications

Enrico Lugli

4 joint publications

Federico Simone Colombo

3 joint publications

Clelia Peano

3 joint publications

Emilia Maria Cristina Mazza